Science-Based Treatment for Opioid-Dependent Adolescents

Phase 2 Unknown 80 enrolled National Development and Research Institutes, Inc. St. Luke's-Roosevelt Hospital Center · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate ways to optimize outcomes from combined behavioral-pharmacological treatment for opioid-dependent youth.

Timeline

Start: 2005-07
Primary completion: —
Completion: —

Outcome

Met primary endpoint

paper 56-day buprenorphine taper had a significantly higher percentage of opioid-negative scheduled urine tests compared with participants who received a 28-day buprenorphine taper PMID 26918564 ↗

paper opioid-negative scheduled urine tests compared with participants who received a 28-day buprenorphine taper [35 versus 17%, P = 0.039 PMID 26918564 ↗

Publications

Marsch LA, Moore SK, Borodovsky JT, Solhkhah R, Badger GJ, Semino S, Jarrett K, Condon KD, Rossettie K, Vincent P, Hajizadeh N, Ducat E. A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults. Addiction. 2016 Aug;111(8):1406-15. doi: 10.1111/add.13363. Epub 2016 Apr 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Buprenorphine	Other / unclassified	—	—
Background	Naltrexone	Small molecule	—	—